ZBIO ZENAS BIOPHARMA
Health Care · Russell 2000
Next earnings: not announced yet
What 10 analyst firms say about ZENAS BIOPHARMA: their latest ratings, price targets and how far the stock is from them. How it works
Analyst window: Latest analyst report within last 1 year
Analyst view · last 1Y
9 rated views · 10 analyst/firm records · 10 firms
Radar score
- Russell 2000 · Top Picks · 6MBelow the Radar threshold of 8065
- Russell 2000 · Safest consensus · 6MBelow the Radar threshold of 8052
Recent analyst activity · last 90 days
Our tracked history has 14 reports on ZBIO from 6 analyst firms in the last 90 days (10 firms in the past year).
Comparing each firm's latest target with its previous one: 5 left it unchanged.
No firm's latest available rating differs from its previous one.
Latest observed target change: Citigroup raised its target from $41.00 (set 17 Mar 2026) to $48.00 on 11 Sep 2026.
Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.
| Firm | Analyst | Latest rating | Report date | Latest target (USD) |
|---|---|---|---|---|
| Citigroup | Yigal Nochomovitz | Buy | 28 Oct 2026 | 48.00 USD · 11 Sep 2026 |
| Evercore ISI | Cory Kasimov | Buy | 1 Jul 2026 | 55.00 USD |
| Guggenheim | Yastin Suneja | Buy | 30 Sep 2026 | 55.00 USD |
| H.C. Wainwright | Matthew Caufield | Buy | 13 Oct 2026 | 44.00 USD |
| Jefferies | Roger Song | Buy | 1 Jul 2026 | 59.00 USD |
| Morgan Stanley | Judah Frommer | Hold | 20 Oct 2026 | 32.00 USD |
| Wedbush | Martin Fan | Buy | 30 Sep 2026 | 45.00 USD |
| Weiss Ratings | Unnamed analyst | — | 23 Oct 2026 | — |
| Wolfe Research | Andy G Chen | Buy | 1 Jul 2026 | 45.00 USD |
| Data feed RESEARCH | Research Team | Hold | 15 May 2026 | — |
Partial coverage · checked 6 Nov (6 Nov 2026, 03:06 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.